Genetic alterations in lung adenocarcinoma with a micropapillary component.

Pulmonary adenocarcinoma (PA) with a micropapillary component (PA-MPC) is known as an aggressive subtype of PA. The molecular profiles of PA-MPC have not been well characterized. the pathological reports of patients who underwent surgical resection for lung cancer between April, 2004 and May, 2012 were reviewed. Of the 674 patients diagnosed with PA, 28 were found to have MPC. A total of 138 resected PAs without MPC were selected in the same period to serve as age-, gender- and smoking status-matched controls to the PA-MPC group. Mutational status was determined by the following two methods: SNaPshot assay based on multiplex polymerase chain reaction (PCR), primer extension and capillary electrophoresis that was designed to assess 38 somatic mutations in 8 genes [, endothelial growth factor receptor (), Kirsten rat sarcoma viral oncogene homolog (), mitogen-activated protein kinase kinase 1, neuroblastoma RAS viral oncogene homolog, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit α () and phosphatase and tensin homolog]; and a PCR-based sizing assay that assesses exon 19 (deletions), exon 20 (insertions) and human epidermal growth factor receptor 2 exon 20 (insertions). echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene () was screened by ALK immunohistochemistry and confirmed using the reverse transcription PCR assay and the break-apart fluorescence hybridization assay. Regarding genetic alterations, 13 (46.4%) of the 28 PA-MPCs harbored mutually exclusive mutations: 9 (32.1%) mutations, 1 (3.6%) mutation and 3 (10.7%) fusion genes. PAs without MPC harbored 42 (30.4%) mutations, 17 (12.3%) mutations, 3 (2.2%) fusion genes and 1 (0.7%) mutation. fusion genes appeared to occur significantly more frequently in PA-MPCs compared with PAs without MPC (P=0.027). Although the sample size was small, our study suggests that the molecular pathogenesis of PA-MPC may be different from that of other adenocarcinomas.